Versartis Lands $55,000,000 Series E Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    275 Shoreline Drive Mountain View, CA 94065
  • Company Description
    Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series E
  • Proceeds Purposes
    The proceeds from this financing will primarily be used to prepare for an international Phase 3 pediatric GHD trial of VRS-317, the company’s proprietary long-acting rhGH for the treatment of GHD.
  • M&A Terms
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    Aisling Capital
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Advent Venture Partners
  • Venture Investor

Trending on Xconomy